Solitary plasmacytomas (SP) are rare, localized tumors composed of clonal plasma cells. They occur either in the bone or soft tissue and must be distinguished from multiple myeloma, which requires systemic treatment. Approximately 50% of patients with solitary bone plasmacytoma progress to multiple myeloma within 5 years of definitive local radiation therapy compared with approximately 30% of those with solitary extramedullary plasmacytoma.

The International Myeloma Working Group recently published a comprehensive update to the recommendations for the diagnosis and management of SP. The consensus highlighted advances in imaging and laboratory testing that can more accurately determine whether the disease is truly localized or whether additional lesions or bone marrow involvement suggest systemic disease.

Advanced Imaging

Historically, diagnosis has relied on conventional x-rays, which lack sufficient sensitivity to detect additional lesions. These updated recommendations call for advanced functional imaging, such as PET or whole-body MRI, to identify otherwise undetected lesions. Finding additional diseases can change the diagnosis from SP to multiple myeloma and alter the treatment approach from local to systemic therapy.

Bone marrow assessment is also an essential part of diagnostic evaluation. Sensitive methods should be used to determine whether clonal plasma cells are present and, if so, whether bone marrow involvement is minimal, defined as less than 10% clonal plasma cells. The recommendations distinguish between SP without bone marrow involvement and SP with minimal bone marrow involvement. Although this distinction provides important prognostic information, the initial treatment approach remains similar regardless of minimal bone marrow involvement.

Radiation Therapy

Despite the availability of newer drugs for plasma cell disorders, local radiation therapy remains the mainstay treatment for SP. The international recommendations have established the following key guidelines:

• Administer a total radiation dose of 40-50 Gy to the affected area.
• Use modern intensity-modulated radiation therapy techniques to precisely target the affected area and minimize toxicity to adjacent healthy organs.
• Avoid adjuvant systemic therapy, reserving it for clinical trials or exceptional and clearly justified cases.

On the other hand, surgery is reserved for specific and urgent situations. It is primarily used to address serious mechanical complications, such as spinal cord compression or bone fractures, but it does not replace radiation therapy for eradicating the primary tumor.

Long-Term Follow-Up

Posttreatment follow-up is essential for monitoring response and detecting recurrence. After completing radiation therapy, the guidelines recommend a comprehensive evaluation with advanced imaging 6-9 months after treatment. If complete remission is confirmed, imaging should be repeated annually during the first 5 years of follow-up.

Monoclonal proteins should also be monitored regularly in the blood and urine. These tests should be performed and reviewed every 3-6 months. Monoclonal protein levels may take time to return to normal after radiation therapy, but persistent or recurrent detection on follow-up testing can be an early warning sign of progression to multiple myeloma.

Clinical Vigilance

SP requires careful evaluation to rule out underlying asymptomatic multiple myeloma. Follow-up should include a high level of clinical vigilance for new bone pain, particularly pain with mechanical or inflammatory features, emerging neurologic symptoms, or unexpected changes in routine laboratory tests. Because some patients progress to systemic disease, coordinated follow-up of monoclonal protein levels and imaging is essential for detecting relapses early and guiding timely treatment.

This story was translated from Univadis Spain, part of the Medscape Professional Network.